Hybrid Intelligence for Trustable Diagnosis and Patient Management of Prostate Cancer (HIT-PIRADS)

Eligibility Criteria

• * Elevated PSA (4.0-10.0 ng/ml) or abnormal digital rectal exam with PSA of 2.00-10.00 ng/ml as indicated in the patient's lab report.
• * Patients must be biopsy naïve, confirmed with patient or medical record.
• * Patients must be male, ≥18 and ≤ 89 years of age.
• * Patient must have a life expectancy ≥10 years, determined by PI.
• * Patients must exhibit an ECOG performance status of 0-2, as noted in their medical record.
• * Patients who are on a 5-α-reductase inhibitor within 12 months of enrollment, as confirmed by medical record.
• * Patients who have had a prostate infection within 1 month of enrollment, as confirmed by medical record.
• * Patients who are receiving or who received prostate cancer treatment (e.g., androgen deprivation therapy, surgery, radiation therapy or adjuvant/neoadjuvant therapy with investigational drugs) per their medical record.
• * Patients who've had an invasive urological procedure within 1 month of enrollment, as confirmed by their medical record and patient reporting.
• * Patients with no access to the rectum for a transrectal ultrasound, as determined by the Urologist.
• * Patients with a contraindication to magnetic resonance imaging (MRI).
• * Vulnerable populations: Prisoners or adult men \>89 years old.